ClinicalTrials.gg
Drug

Trabectedin clinical trials

Also written Yondelis and ET-743.

studies test it
73
open now
10
in phase 3
13
first study started
1996

How each study uses Trabectedin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Trabectedin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Oct 2015 · YONDELIS · NDA 207953 (FDA, Drugs@FDA)
European Union
17 Sept 2007 · Yondelis · EMEA/H/C/000773 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Trabectedin
60
Ecteinascidin
4
ecteinascidin 743
4

Brand

Yondelis
34

Development codes

ET-743
9

Studies by the year they started

72 studies that test it; most in 2011 (9)

Studies that test Trabectedin, by start year
YearStudies
19961
19991
20001
20012
20024
20031
20041
20051
20061
20073
20084
20091
20103
20119
20121
20133
20144
20153
20161
20176
20186
20194
20203
20214
20221
20252
20261

By phase

A phase 1/2 study counts in both.

Phase 1
15
Phase 2
49
Phase 3
13
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 56

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (10) · Italian Sarcoma Group (7) · Mario Negri Institute for Pharmacological Research (5) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Grupo Espanol de Investigacion en Sarcomas (4) · Janssen Research & Development, LLC (4) · Gustave Roussy, Cancer Campus, Grand Paris (3) · Institut Bergonié (3)

Often tested with

Tested in the same studies.

Doxorubicin (5) · Nivolumab (4) · Gemcitabine (3) · Olaparib (3) · Olaratumab (2) · Bevacizumab (2) · Carboplatin (2) · Pioglitazone (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 2 phase 3 studies under way

Trabectedin is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 2

Studies that test Trabectedin.

Studies

Open first, then newest update. How each study uses Trabectedin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 73

See all 73 studies that test Trabectedin →

Given beside what is tested · 4 — Trabectedin is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with Trabectedin

Codes

What other systems call Trabectedin · ClinicalTrials.gg INT006776

  • MeSH (NLM) D000077606TrabectedinConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) ID0YZQ2TCPTRABECTEDINConfirmed FDA, NLM, Wikidata
  • RxNorm 1716278Confirmed FDA, Wikidata
  • Wikidata Q2637746trabectedinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1691TrabectedinOne source FDA
  • DrugBank DB05109One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.